Skip to main content
Clinical Trials/ACTRN12611000497909
ACTRN12611000497909
Completed
Phase 4

A randomised double-blind placebo-controlled trial to investigate whether paracetamol lengthens the duration of viral shedding in the treatment of patients with influenza

Medical Research Institute of New Zealand0 sites80 target enrollmentMay 12, 2011

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Medical Research Institute of New Zealand
Enrollment
80
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 12, 2011
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Onset of an influenza like illness in the past 48 hours: history of fever or documented temperature greater than or equal to 37\.8 degree celsius, and at least one of cough, sore throat, rhinorrhea, headache, myalgia, fatigue, or malaise

Exclusion Criteria

  • Influenza illness severe enough to warrant hospital admission.
  • A history of allergy or sensitivity or other contraindication to paracetamol or opiates.
  • Subjects using paracetamol or NSAIDS (not including low dose aspirin) regularly who are unwilling or unable to discontinue use during the trial period.
  • Recent treatment with oseltamivir.
  • HIV infection.
  • Current pregnancy.
  • Current treatment with oral corticosteroids or other immunosuppressant drugs.
  • Any other safety concern at the investigator’s discretion.

Outcomes

Primary Outcomes

Not specified

Similar Trials